** Shares of Mirum Pharmaceuticals rise 5.7% to $43.97
** Co raises 2024 rev. forecast to the range of $330 mln to $335 mln from its prior range of $310 mln to $320 mln
** Posts Q3 rev. of $90.3 mln, above analysts' est. of $82.0 mln - LSEG
** Reports Q3 loss per share of 30 cents, smaller than analysts' est. of 45 cents - LSEG
** Co's Livmarli, a liver disease drug, posts Q3 rev. of $59.1 mln, above analysts' est of $50 mln - LSEG
** All 11 brokerages covering MIRM rate the stock "buy" or higher; median PT is $65.50 - LSEG
** Stock has risen ~49% YTD, including session gains
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。